Alfentanil reduces the febrile response to interleukin-2 in humans

OBJECTIVE:Manifestation of intraoperative fever is impaired by volatile anesthetics and muscle relaxants. Opioids are common anesthetic adjuvants and remain the dominant treatment for postoperative surgical pain and sedation of critically ill patients. The effect of opioids on normal thermoregulator...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical care medicine 2000-05, Vol.28 (5), p.1295-1300
Hauptverfasser: Negishi, Chiharu, Kim, Jin-Soo, Lenhardt, Rainer, Sessler, Daniel I, Ozaki, Makoto, Vuong, Kathleen, Bastanmehr, Hiva, Bjorksten, Andrew R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1300
container_issue 5
container_start_page 1295
container_title Critical care medicine
container_volume 28
creator Negishi, Chiharu
Kim, Jin-Soo
Lenhardt, Rainer
Sessler, Daniel I
Ozaki, Makoto
Vuong, Kathleen
Bastanmehr, Hiva
Bjorksten, Andrew R
description OBJECTIVE:Manifestation of intraoperative fever is impaired by volatile anesthetics and muscle relaxants. Opioids are common anesthetic adjuvants and remain the dominant treatment for postoperative surgical pain and sedation of critically ill patients. The effect of opioids on normal thermoregulatory control is well established. However, the extent to which these drugs might inhibit fever remains unknown. Accordingly, we tested the hypothesis that relatively low plasma concentrations of the μ-receptor agonist alfentanil reduce fever magnitude. DESIGN:Prospective, randomized, crossover study. SETTING:Outcomes Research Laboratory, at the Department of Anesthesia and Perioperative Care, University of California, San Francisco. PATIENTS:Eight healthy male volunteers, aged 25-31 yrs, each studied on three separate days. INTERVENTION:Each volunteer was given an intravenous injection of 30 IU/g interleukin (IL)-2, followed 2 hrs later by 70 IU/g. One hour after the second dose, the volunteers were randomly assigned to three doses of alfentanila) none (control); b) a target plasma concentration of 100 ng/mL; and c) a target concentration of 200 ng/mL. Opioid administration continued for 5 hrs. METHODS AND MAIN RESULTS:Alfentanil significantly reduced the febrile response to pyrogen, decreasing integrated tympanic membrane temperatures from 7.5 ± 2.2°C·hr on the control day, to 4.9 ± 1.5°C·hr with 100 ng/mL alfentanil, and to 5.1 ± 1.7°C·hr with 200 ng/mL alfentanil (p = .011). Peak temperatures were also significantly reduced from 38.5 ± 0.4°C on the control day, to 38.0 ± 0.4°C on the 100 ng/mL-alfentanil day and 38.0 ± 0.6°C on the 200-ng/mL day (p = .019). Plasma cytokine concentrations increased after IL-2 administration, roughly in proportion to the elevation in core temperature. However, cytokine concentrations did not differ significantly among the treatment groups. CONCLUSION:Alfentanil significantly reduced the febrile response to IL-2 administration. However, the reduction was comparable at plasma concentrations near 100 and 200 ng/mL. These data indicate that concentrations of opioids commonly observed in critical care patients significantly inhibit the manifestation of fever.
doi_str_mv 10.1097/00003246-200005000-00006
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71148827</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71148827</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3566-a48517bdf5a295280db153201f93d4e3ff48ef7b4e61b8b9cbaf00035e8e22a13</originalsourceid><addsrcrecordid>eNp1kUtLxDAQx4Mo7rr6FaQnb9W8mqbHdfEFghc9h6Sd0LppuyYti9_e1K7ixYEwD_4zk_yCUELwNcFFfoOjMcpFSqcoiyedAnGEliRjMaEFO0ZLjAucMl6wBToL4R1jwrOcnaIFwZJxIeQS3a6dhW7QXeMSD9VYQkiGGhILxjcOYi3s-i5AMvRJ0w3gHYzbpktpzJJ6bHUXztGJ1S7AxcGv0Nv93evmMX1-eXjarJ_TkmVCpJrLjOSmspmmRUYlrky8K8XEFqziwKzlEmxuOAhipClKo-30zAwkUKoJW6Gree7O9x8jhEG1TSjBOd1BPwaVE8KlpHkUyllY-j4ED1btfNNq_6kIVhM_9cNP_fL7LonYennYMZoWqj-NM7Ao4LNg37tII2zduAevatBuqNV__8K-AD5bec8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71148827</pqid></control><display><type>article</type><title>Alfentanil reduces the febrile response to interleukin-2 in humans</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Negishi, Chiharu ; Kim, Jin-Soo ; Lenhardt, Rainer ; Sessler, Daniel I ; Ozaki, Makoto ; Vuong, Kathleen ; Bastanmehr, Hiva ; Bjorksten, Andrew R</creator><creatorcontrib>Negishi, Chiharu ; Kim, Jin-Soo ; Lenhardt, Rainer ; Sessler, Daniel I ; Ozaki, Makoto ; Vuong, Kathleen ; Bastanmehr, Hiva ; Bjorksten, Andrew R</creatorcontrib><description>OBJECTIVE:Manifestation of intraoperative fever is impaired by volatile anesthetics and muscle relaxants. Opioids are common anesthetic adjuvants and remain the dominant treatment for postoperative surgical pain and sedation of critically ill patients. The effect of opioids on normal thermoregulatory control is well established. However, the extent to which these drugs might inhibit fever remains unknown. Accordingly, we tested the hypothesis that relatively low plasma concentrations of the μ-receptor agonist alfentanil reduce fever magnitude. DESIGN:Prospective, randomized, crossover study. SETTING:Outcomes Research Laboratory, at the Department of Anesthesia and Perioperative Care, University of California, San Francisco. PATIENTS:Eight healthy male volunteers, aged 25-31 yrs, each studied on three separate days. INTERVENTION:Each volunteer was given an intravenous injection of 30 IU/g interleukin (IL)-2, followed 2 hrs later by 70 IU/g. One hour after the second dose, the volunteers were randomly assigned to three doses of alfentanila) none (control); b) a target plasma concentration of 100 ng/mL; and c) a target concentration of 200 ng/mL. Opioid administration continued for 5 hrs. METHODS AND MAIN RESULTS:Alfentanil significantly reduced the febrile response to pyrogen, decreasing integrated tympanic membrane temperatures from 7.5 ± 2.2°C·hr on the control day, to 4.9 ± 1.5°C·hr with 100 ng/mL alfentanil, and to 5.1 ± 1.7°C·hr with 200 ng/mL alfentanil (p = .011). Peak temperatures were also significantly reduced from 38.5 ± 0.4°C on the control day, to 38.0 ± 0.4°C on the 100 ng/mL-alfentanil day and 38.0 ± 0.6°C on the 200-ng/mL day (p = .019). Plasma cytokine concentrations increased after IL-2 administration, roughly in proportion to the elevation in core temperature. However, cytokine concentrations did not differ significantly among the treatment groups. CONCLUSION:Alfentanil significantly reduced the febrile response to IL-2 administration. However, the reduction was comparable at plasma concentrations near 100 and 200 ng/mL. These data indicate that concentrations of opioids commonly observed in critical care patients significantly inhibit the manifestation of fever.</description><identifier>ISSN: 0090-3493</identifier><identifier>EISSN: 1530-0293</identifier><identifier>DOI: 10.1097/00003246-200005000-00006</identifier><identifier>PMID: 10834668</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins, Inc</publisher><subject>Adult ; Alfentanil - pharmacology ; Analgesics, Opioid - pharmacology ; Body Temperature Regulation - drug effects ; Body Temperature Regulation - physiology ; Dose-Response Relationship, Drug ; Fever - chemically induced ; Fever - physiopathology ; Humans ; Interleukin-2 - pharmacology ; Male</subject><ispartof>Critical care medicine, 2000-05, Vol.28 (5), p.1295-1300</ispartof><rights>2000 Lippincott Williams &amp; Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3566-a48517bdf5a295280db153201f93d4e3ff48ef7b4e61b8b9cbaf00035e8e22a13</citedby><cites>FETCH-LOGICAL-c3566-a48517bdf5a295280db153201f93d4e3ff48ef7b4e61b8b9cbaf00035e8e22a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10834668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Negishi, Chiharu</creatorcontrib><creatorcontrib>Kim, Jin-Soo</creatorcontrib><creatorcontrib>Lenhardt, Rainer</creatorcontrib><creatorcontrib>Sessler, Daniel I</creatorcontrib><creatorcontrib>Ozaki, Makoto</creatorcontrib><creatorcontrib>Vuong, Kathleen</creatorcontrib><creatorcontrib>Bastanmehr, Hiva</creatorcontrib><creatorcontrib>Bjorksten, Andrew R</creatorcontrib><title>Alfentanil reduces the febrile response to interleukin-2 in humans</title><title>Critical care medicine</title><addtitle>Crit Care Med</addtitle><description>OBJECTIVE:Manifestation of intraoperative fever is impaired by volatile anesthetics and muscle relaxants. Opioids are common anesthetic adjuvants and remain the dominant treatment for postoperative surgical pain and sedation of critically ill patients. The effect of opioids on normal thermoregulatory control is well established. However, the extent to which these drugs might inhibit fever remains unknown. Accordingly, we tested the hypothesis that relatively low plasma concentrations of the μ-receptor agonist alfentanil reduce fever magnitude. DESIGN:Prospective, randomized, crossover study. SETTING:Outcomes Research Laboratory, at the Department of Anesthesia and Perioperative Care, University of California, San Francisco. PATIENTS:Eight healthy male volunteers, aged 25-31 yrs, each studied on three separate days. INTERVENTION:Each volunteer was given an intravenous injection of 30 IU/g interleukin (IL)-2, followed 2 hrs later by 70 IU/g. One hour after the second dose, the volunteers were randomly assigned to three doses of alfentanila) none (control); b) a target plasma concentration of 100 ng/mL; and c) a target concentration of 200 ng/mL. Opioid administration continued for 5 hrs. METHODS AND MAIN RESULTS:Alfentanil significantly reduced the febrile response to pyrogen, decreasing integrated tympanic membrane temperatures from 7.5 ± 2.2°C·hr on the control day, to 4.9 ± 1.5°C·hr with 100 ng/mL alfentanil, and to 5.1 ± 1.7°C·hr with 200 ng/mL alfentanil (p = .011). Peak temperatures were also significantly reduced from 38.5 ± 0.4°C on the control day, to 38.0 ± 0.4°C on the 100 ng/mL-alfentanil day and 38.0 ± 0.6°C on the 200-ng/mL day (p = .019). Plasma cytokine concentrations increased after IL-2 administration, roughly in proportion to the elevation in core temperature. However, cytokine concentrations did not differ significantly among the treatment groups. CONCLUSION:Alfentanil significantly reduced the febrile response to IL-2 administration. However, the reduction was comparable at plasma concentrations near 100 and 200 ng/mL. These data indicate that concentrations of opioids commonly observed in critical care patients significantly inhibit the manifestation of fever.</description><subject>Adult</subject><subject>Alfentanil - pharmacology</subject><subject>Analgesics, Opioid - pharmacology</subject><subject>Body Temperature Regulation - drug effects</subject><subject>Body Temperature Regulation - physiology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Fever - chemically induced</subject><subject>Fever - physiopathology</subject><subject>Humans</subject><subject>Interleukin-2 - pharmacology</subject><subject>Male</subject><issn>0090-3493</issn><issn>1530-0293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtLxDAQx4Mo7rr6FaQnb9W8mqbHdfEFghc9h6Sd0LppuyYti9_e1K7ixYEwD_4zk_yCUELwNcFFfoOjMcpFSqcoiyedAnGEliRjMaEFO0ZLjAucMl6wBToL4R1jwrOcnaIFwZJxIeQS3a6dhW7QXeMSD9VYQkiGGhILxjcOYi3s-i5AMvRJ0w3gHYzbpktpzJJ6bHUXztGJ1S7AxcGv0Nv93evmMX1-eXjarJ_TkmVCpJrLjOSmspmmRUYlrky8K8XEFqziwKzlEmxuOAhipClKo-30zAwkUKoJW6Gree7O9x8jhEG1TSjBOd1BPwaVE8KlpHkUyllY-j4ED1btfNNq_6kIVhM_9cNP_fL7LonYennYMZoWqj-NM7Ao4LNg37tII2zduAevatBuqNV__8K-AD5bec8</recordid><startdate>200005</startdate><enddate>200005</enddate><creator>Negishi, Chiharu</creator><creator>Kim, Jin-Soo</creator><creator>Lenhardt, Rainer</creator><creator>Sessler, Daniel I</creator><creator>Ozaki, Makoto</creator><creator>Vuong, Kathleen</creator><creator>Bastanmehr, Hiva</creator><creator>Bjorksten, Andrew R</creator><general>Lippincott Williams &amp; Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200005</creationdate><title>Alfentanil reduces the febrile response to interleukin-2 in humans</title><author>Negishi, Chiharu ; Kim, Jin-Soo ; Lenhardt, Rainer ; Sessler, Daniel I ; Ozaki, Makoto ; Vuong, Kathleen ; Bastanmehr, Hiva ; Bjorksten, Andrew R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3566-a48517bdf5a295280db153201f93d4e3ff48ef7b4e61b8b9cbaf00035e8e22a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Alfentanil - pharmacology</topic><topic>Analgesics, Opioid - pharmacology</topic><topic>Body Temperature Regulation - drug effects</topic><topic>Body Temperature Regulation - physiology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Fever - chemically induced</topic><topic>Fever - physiopathology</topic><topic>Humans</topic><topic>Interleukin-2 - pharmacology</topic><topic>Male</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Negishi, Chiharu</creatorcontrib><creatorcontrib>Kim, Jin-Soo</creatorcontrib><creatorcontrib>Lenhardt, Rainer</creatorcontrib><creatorcontrib>Sessler, Daniel I</creatorcontrib><creatorcontrib>Ozaki, Makoto</creatorcontrib><creatorcontrib>Vuong, Kathleen</creatorcontrib><creatorcontrib>Bastanmehr, Hiva</creatorcontrib><creatorcontrib>Bjorksten, Andrew R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Negishi, Chiharu</au><au>Kim, Jin-Soo</au><au>Lenhardt, Rainer</au><au>Sessler, Daniel I</au><au>Ozaki, Makoto</au><au>Vuong, Kathleen</au><au>Bastanmehr, Hiva</au><au>Bjorksten, Andrew R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alfentanil reduces the febrile response to interleukin-2 in humans</atitle><jtitle>Critical care medicine</jtitle><addtitle>Crit Care Med</addtitle><date>2000-05</date><risdate>2000</risdate><volume>28</volume><issue>5</issue><spage>1295</spage><epage>1300</epage><pages>1295-1300</pages><issn>0090-3493</issn><eissn>1530-0293</eissn><abstract>OBJECTIVE:Manifestation of intraoperative fever is impaired by volatile anesthetics and muscle relaxants. Opioids are common anesthetic adjuvants and remain the dominant treatment for postoperative surgical pain and sedation of critically ill patients. The effect of opioids on normal thermoregulatory control is well established. However, the extent to which these drugs might inhibit fever remains unknown. Accordingly, we tested the hypothesis that relatively low plasma concentrations of the μ-receptor agonist alfentanil reduce fever magnitude. DESIGN:Prospective, randomized, crossover study. SETTING:Outcomes Research Laboratory, at the Department of Anesthesia and Perioperative Care, University of California, San Francisco. PATIENTS:Eight healthy male volunteers, aged 25-31 yrs, each studied on three separate days. INTERVENTION:Each volunteer was given an intravenous injection of 30 IU/g interleukin (IL)-2, followed 2 hrs later by 70 IU/g. One hour after the second dose, the volunteers were randomly assigned to three doses of alfentanila) none (control); b) a target plasma concentration of 100 ng/mL; and c) a target concentration of 200 ng/mL. Opioid administration continued for 5 hrs. METHODS AND MAIN RESULTS:Alfentanil significantly reduced the febrile response to pyrogen, decreasing integrated tympanic membrane temperatures from 7.5 ± 2.2°C·hr on the control day, to 4.9 ± 1.5°C·hr with 100 ng/mL alfentanil, and to 5.1 ± 1.7°C·hr with 200 ng/mL alfentanil (p = .011). Peak temperatures were also significantly reduced from 38.5 ± 0.4°C on the control day, to 38.0 ± 0.4°C on the 100 ng/mL-alfentanil day and 38.0 ± 0.6°C on the 200-ng/mL day (p = .019). Plasma cytokine concentrations increased after IL-2 administration, roughly in proportion to the elevation in core temperature. However, cytokine concentrations did not differ significantly among the treatment groups. CONCLUSION:Alfentanil significantly reduced the febrile response to IL-2 administration. However, the reduction was comparable at plasma concentrations near 100 and 200 ng/mL. These data indicate that concentrations of opioids commonly observed in critical care patients significantly inhibit the manifestation of fever.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins, Inc</pub><pmid>10834668</pmid><doi>10.1097/00003246-200005000-00006</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-3493
ispartof Critical care medicine, 2000-05, Vol.28 (5), p.1295-1300
issn 0090-3493
1530-0293
language eng
recordid cdi_proquest_miscellaneous_71148827
source MEDLINE; Journals@Ovid Complete
subjects Adult
Alfentanil - pharmacology
Analgesics, Opioid - pharmacology
Body Temperature Regulation - drug effects
Body Temperature Regulation - physiology
Dose-Response Relationship, Drug
Fever - chemically induced
Fever - physiopathology
Humans
Interleukin-2 - pharmacology
Male
title Alfentanil reduces the febrile response to interleukin-2 in humans
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T17%3A50%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alfentanil%20reduces%20the%20febrile%20response%20to%20interleukin-2%20in%20humans&rft.jtitle=Critical%20care%20medicine&rft.au=Negishi,%20Chiharu&rft.date=2000-05&rft.volume=28&rft.issue=5&rft.spage=1295&rft.epage=1300&rft.pages=1295-1300&rft.issn=0090-3493&rft.eissn=1530-0293&rft_id=info:doi/10.1097/00003246-200005000-00006&rft_dat=%3Cproquest_cross%3E71148827%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71148827&rft_id=info:pmid/10834668&rfr_iscdi=true